Motretinide
{{Verification|date=November 2023}}{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444560893
| ImageFile=Motretinide.svg
| IUPACName=N-Ethyl-3-methoxy-2-methyl-1,2,3,4-tetradehydro-17-norretinamide
| SystematicName=(2E,4E,6E,8E)-N-Ethyl-8-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenamide
| OtherNames=
|Section1={{Chembox Identifiers
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = W786807KL1
| CASNo_Ref = {{cascite|correct|CAS}}
| CASNo=56281-36-8
| EINECS = 260-094-6
| PubChem = 6314185
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 4880635
| SMILES = CCNC(=O)/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C(=C(C=C1C)OC)C)C
| InChI = 1/C23H31NO2/c1-8-24-23(25)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(26-7)20(6)19(21)5/h9-15H,8H2,1-7H3,(H,24,25)/b11-9+,13-12+,16-10+,17-14+
| InChIKey = IYIYMCASGKQOCZ-DJRRULDNBU
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C23H31NO2/c1-8-24-23(25)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(26-7)20(6)19(21)5/h9-15H,8H2,1-7H3,(H,24,25)/b11-9+,13-12+,16-10+,17-14+
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = IYIYMCASGKQOCZ-DJRRULDNSA-N
| RTECS =
| MeSHName =
| ChEBI =
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D05082
}}
|Section2={{Chembox Properties
| Formula=C23H31NO2
| MolarMass=353.49774
| Appearance=
| Density=
| MeltingPt=
| BoilingPt=
| Solubility=
}}
|Section6={{Chembox Pharmacology
| ATCCode_prefix = D10
| ATCCode_suffix = AD05
}}
|Section7={{Chembox Hazards
| MainHazards=
| FlashPt=
| AutoignitionPt =
}}
}}
Motretinide is an anti-acne preparation and aromatic analog of retinoic acid.{{Cite journal
| last1 = Zouboulis | first1 = C. C.
| title = Retinoids--which dermatological indications will benefit in the near future?
| journal = Skin Pharmacology and Applied Skin Physiology
| volume = 14
| issue = 5
| pages = 303–315
| year = 2001
| pmid = 11586072
| doi = 10.1159/000056361
}}